First Allied Advisory Services’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

First Allied Advisory Services’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,098	Closed	-$300K	–	1115
2016 Q2	$300K	Buy	+2,098	New	+$306K	0.02%	743

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First Allied Advisory Services's ICPT Position: Q3 2016 in Review

First Allied Advisory Services sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2016, closing a stake of 2,098 shares — an estimated $300K sold.

First Allied Advisory Services first reported a position in ICPT in Q2 2016 and held it in 1 quarter. The position peaked at $300K in Q2 2016. 172 funds tracked by Wall St. Rank hold ICPT as of Q3 2016.

First Allied Advisory Services reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
First Allied Advisory Services sold 2,098 Intercept Pharmaceuticals, Inc. shares in Q3 2016, an estimated $300K.
First Allied Advisory Services first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
First Allied Advisory Services's Intercept Pharmaceuticals, Inc. position peaked at $300K in Q2 2016.
172 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2016.

Based on First Allied Advisory Services's 13F filing for Q3 2016, filed 14 Nov 2016.